NXI Therapeutics: Funding, Investors & Team (Sep 2026)
NXI Therapeutics is a company that specializes in creating new immunosuppressive medications to treat autoimmune diseases and aid in organ transplantation. Led by CEO Ruben Herrendorff, who has significant expertise in drug research for autoimmune and neuromuscular diseases, the company focuses on developing highly effective treatments. NXI Therapeutics is dedicated to tackling difficult medical issues and advancing the biotechnology industry through its research efforts.
NXI Therapeutics has raised $3.9M across 1 funding round on record, the most recent a Pre-Seed of $3.9M announced in Jun 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
NXI Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2024.
NXI Therapeutics Funding Rounds
NXI Therapeutics Founders and Leadership Team
Contact details for the NXI Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →NXI Therapeutics Funding Compared to Other Biotechnology Startups
NXI Therapeutics' latest round of $3.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like NXI Therapeutics in Biotechnology and Basel
Companies Similar to NXI Therapeutics
Adaptyv Biosystems developing a protein engineering platform using cell-free synthetic biology and…
At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful…
compliag is providing agile solutions for regulated industries, including the licencing, manufacturing and…
MoonLake Immunotherapeutics is a biopharmaceutical company in the clinical stage that is developing new…
Isospec Analytics SA is a life science company that aims at simplifying molecular identification. We are…
Cria Technologies reinvents cold-chain transport with high-vacuum insulation technology that offers…
Precise Health is a phage therapy platform that specialises in improving and treating bacterial infections to…
AC Immune is a biopharmaceutical company based in Switzerland that is currently in the clinical stage. They…
AlveoliX provides in-vitro solutions based on proprietary and unique organ-on-chip technologies aimed at…
Combioxin SA is clinical-stage biotech company developing innovative anti-virulence drugs to treat severe…
MindMaze is a digital neurotherapeutic platform that provides digital assessments and therapeutics to treat…
Neurosoft Bioelectronics is developing next-generation soft implantable electrodes to interface with the…
NXI Therapeutics Funding FAQs
What does NXI Therapeutics do?
NXI Therapeutics is a company that specializes in creating new immunosuppressive medications to treat autoimmune diseases and aid in organ transplantation. Led by CEO Ruben Herrendorff, who has significant expertise in drug research for autoimmune and neuromuscular diseases, the company focuses on developing highly effective treatments. NXI Therapeutics is dedicated to tackling difficult medical issues and advancing the biotechnology industry through its research efforts.
How much funding has NXI Therapeutics raised?
NXI Therapeutics has raised $3.9M across 1 round on record. The most recent is a Pre-Seed of $3.9M announced in Jun 2024.
When did NXI Therapeutics last raise funding?
NXI Therapeutics' most recent funding round on record is a Pre-Seed of $3.9M, announced in Jun 2024.
Who founded NXI Therapeutics?
FundedIQ lists Ruben Herrendorff (Founder) at NXI Therapeutics.
Where is NXI Therapeutics headquartered?
NXI Therapeutics is based in Basel, Basel-Stadt, Switzerland.
How many employees does NXI Therapeutics have?
NXI Therapeutics is in the 1-10 employee band.
How does NXI Therapeutics' funding compare to other Biotechnology startups?
NXI Therapeutics' latest round of $3.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's NXI Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for NXI Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.